Repoceuticals

We develop medicinal products expected to meet a high unmet need to reduce significant and severe side effects of radiotherapy and cytotoxic therapy in treatment of cancer, and to relief the devastating symptoms and chronic consequences of low anterior resection syndrome.

LEARN MORE

About us

RepoCeuticals’ strategy is to reposition, reroute and recombine natural agents for new prophylactic and therapeutic uses for reducing the significant and severe side effects of radiotherapy and cytotoxic therapy in treatment of cancer, and for new therapeutic uses for relieving the devastating symptoms and chronic consequences of low anterior resection syndrome.

Repositioning

Repositioning is a new use for an established therapeutic agent. This entails registration and using the agent for a different indication i.e. treating another condition than its previous registered use.

Rerouting

Rerouting is changing the route of administration of the active ingredient to one that is suitable for the new indication. RepoCeuticals formulates the active ingredients to suit local administration at the specific physical site where they need to act.

Combining

Combining different active substances that act in different ways to achieve an additive or synergistic effect. The best generally applicable combination is developed for a given indication.

The lead compound

Melatonin

Melatonin is a natural hormone of small molecular size produced in most animals and in plants. In human beings and other mammals, it originates from the pineal gland, positioned on a stalk between the forebrain and hindbrain. In mammals, it has a circadian secretion pattern with the highest circulating concentrations occurring at night.